Other Events ·
Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on July 20, 2026
RNTXRein Therapeutics, Inc.
Rein Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on July 20, 2026. Shareholders elected Josef H. von Rickenbach and Reinhard J. Ambros, Ph.D. as Class III directors. Stockholders approved an amendment to the restated certificate of incorporation to increase authorized common stock from 100 million to 200 million shares. Additionally, the meeting resulted in the ratification of CBIZ CPAs P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and the advisory approval of executive officer compensation. Rein Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions.